Total medical devices industry venture financing deals worth $351.2m were announced in Asia-Pacific in August 2021, led by $100m venture financing of Pulse Medical Imaging Technology (Shanghai), according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked a decrease of 48.02% over the previous month of $675.73m and a drop of 23.05% when compared with the last 12-month average of $456.48m.
Asia-Pacific held an 18.99% share of the global medical devices industry venture financing deal value that totalled $1.85bn in August 2021. With a 17.08% share and deals worth $316m, China was the top country in Asia-Pacific’s venture financing deal value across medical devices industry.
In terms of venture financing deal activity, Asia-Pacific recorded 24 deals during August 2021, marking a decrease of 54.72% over the previous month and a drop of 17.24% over the 12-month average. China recorded 15 deals during the month.
Asia-Pacific medical devices industry venture financing deals in August 2021: Top deals
The top five medical devices industry venture financing deals accounted for 85.9% of the overall value during August 2021.
The combined value of the top five medical devices venture financing deals stood at $301.67m, against the overall value of $351.2m recorded for the month.
The top five medical devices industry venture financing deals of August 2021 tracked by GlobalData were:
1) Boyu Capital Consultancy,GL Ventures,Goldman Sachs Group,Insight Capital,Koninklijke Philips and Linden Asset Management $100m venture financing deal with Pulse Medical Imaging Technology (Shanghai)
2) The $99.15m venture financing of Berry Oncology by China Merchants Capital Management,E Fund Management,Fujian Venture Investment Management,Legend Capital,Qiming Venture Partners,Xiamen C&D Emerging Industry Equity Investment and Zhongjin Qichen Industry Equity Investment Fund
4) The $23.15m venture financing of Amor (Suzhou) Medical Sci-Tech by Beijing Yi Ling Capital Management,CDH VGC,Huiding Capital Management,Junmao Capital,Su Gaoxin Venture Capital Group and Yantai Baofu Investment Center